Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round
By Dean Seal
Shares of Applied Therapeutics soared after the company disclosed a $100 million private placement and said regulators have granted priority review for its lead drug candidate govorestat.
The stock was up 54% at $8.59 in premarket trading. Shares had already risen by two thirds year-to-date when the market closed Tuesday.
The clinical-stage biopharmaceutical company said Wednesday morning the Food and Drug Administration has accepted the filing of a new drug application for govorestat as a treatment for classic galactosemia.
The application was granted priority review status and a key target action date was set for Aug. 28. The FDA also plans to hold an advisory committee meeting to discuss the application.
Applied Therapeutics concurrently announced that it has entered into a $100 million securities purchase agreement with large healthcare-focused institutional and mutual fund investors.
Proceeds from the private placement are expected to extend the company's cash runway into 2026.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 28, 2024 08:40 ET (13:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst